T淋巴细胞亚群与白细胞介素-6在多发性骨髓瘤患者中的表达

杨达天; 姚福生; 梁虹; 徐海涛; 潘明

doi:10.13201/j.issn.1004-2806.2015.09.009

T淋巴细胞亚群与白细胞介素-6在多发性骨髓瘤患者中的表达

- 1 安徽医科大学附属安庆医院血液科(安徽安庆, 246003)

详细信息

通讯作者: 姚福生,E-mail:374860736@qq.com

中图分类号: R733.3

收稿日期: 2015-02-02

Expression of T lymphocyte subsets and interleukin-6in patients with multiple myeloma

- Department of Hematology, Anqing Hospital Affiliated to Anhui Medical Univesity, Anqing, 246003, China

More Information

Corresponding author: YAO Fusheng, E-mail: 374860736@qq.com

Received Date: 02 February 2015

摘要

摘要: 目的:探讨不同分期的多发性骨髓瘤(MM)患者外周血淋巴细胞各亚群细胞比例与白细胞介素-6(IL-6)表达变化。方法:用流式细胞仪检测35例初治MM患者及10例对照者的外周血淋巴细胞亚群各细胞表达水平,用ELISA法检测IL-6水平。结果:与对照者相比,MM患者的CD4⁺、CD4⁺/CD8⁺明显降低(P<0.01),均与MM分期严重程度呈负相关(r=-0.780,-0.832,P<0.01);MM患者的CD8⁺显著增加(P<0.01),与MM分期严重程度呈正相关(r=0.737,P<0.01)。MM患者的IL-6水平较对照者显著增加,与MM分期严重程度呈正相关(r=0.961,P<0.01)。结论:IL-6表达增加及T淋巴细胞亚群数目异常变化可能是MM患者免疫异常的机制之一,两者能作为观察MM患者病情严重程度的指标。
- 多发性骨髓瘤 /
- T淋巴细胞亚群 /
- 白细胞介素-6
Abstract: Objective:To investigate the changes of T lymphocytes subsets and expression of interleukin-6 (IL-6) in peripheral blood of the patients with multiple myeloma (MM) in different stages.Method:The peripheral blood was collected from 35 newly diagnosed patients with MM and 10 normal controls.Flow cytometry was used to detect T lymphocyte subsets in peripheral blood,and enzyme-linked immunosorbent assay was used to determine the level of IL-6.Result:Compared with normal controls,the number of CD4⁺ and the ratio of CD4⁺/CD8⁺ in MM patients decreased significantly (P<0.01),and were negatively correlated with the degree of MM (r=-0.780,-0.832,P<0.01);The number of CD8⁺ increased significantly,and was positively related with the degree of MM (r=0.737,P<0.01);The level of IL-6 increased significantly,and was positively related with the degree of MM (r=0.961,P<0.01).Conclusion:Increase of IL-6 expression and abnormality of T lymphocyte subsets may be one of the mechanisms for cellular immun dysfunction in patients with MM,both of them can serve as indexes for observing the disease state.
- multiple myeloma /
- T lymphocyte subsets /
- interleukin-6

HTML全文

参考文献(8)

[1]	张之南,沈悌.血液学诊断及疗效标准[M].3版.北京:科学出版社,2007:232-235.
[2]	Goodyear OC,Pratt G,McLarnon A,et al.Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance(MGUS) and multiple myeloma[J].Blood,2008,112:3362-3372.
[3]	陈苗,许莹,李辉,等.34例新诊断多发性骨髓瘤患者淋巴细胞亚群及相关预后因素分析[J].中华血液学杂志,2013,34(4):355-358.
[4]	郭益群,陈世伦.多发性骨髓瘤骨髓基质细胞分泌IGF-1、VEGF和IL-6的动态变化[J].中华血液学杂志,2006,27(4):231-234.
[5]	Fedele G,Di Girolamo M,Recine U,et al.CD38 ligation in peripheral blood mononuclear cells of myeloma patientsinduces release of protumorigenic IL-6 and impaired secretion of IFNγ cytokines and proliferation[J].Mediators Inflamm,2013,2013:564687.
[6]	Guichelaar T,Emmelot ME,Rozemuller H,et al.Human regulatory T cells do not suppress the antitumor immunity in the bone marrow:a role for bone marrow stromal cells in neutralizing regulatory T cells[J].Clin Cancer Res,2013,19:1467-1475.
[7]	Semeraro M,Vacchelli E,Eggermont A,et al.Trial Watch:Lenalidomide-based immunochemotherapy[J].Oncoimmunology,2013,2:e26494.
[8]	邢立杰,徐燕,安刚,等.初治多发性骨髓瘤患者血清IL-6的预后价值[J].中国实验血液学杂志,2013,21(6):1492-1495.